These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Genes for albicidin biosynthesis and resistance span at least 69 kb in the genome of Xanthomonas albilineans. Wall MK; Birch RG Lett Appl Microbiol; 1997 Apr; 24(4):256-60. PubMed ID: 9134771 [TBL] [Abstract][Full Text] [Related]
25. Biochemical properties of inducible beta-lactamases produced from Xanthomonas maltophilia. Paton R; Miles RS; Amyes SG Antimicrob Agents Chemother; 1994 Sep; 38(9):2143-9. PubMed ID: 7811033 [TBL] [Abstract][Full Text] [Related]
30. Xanthomonas maltophilia: an emerging nosocomial pathogen. Marshall WF; Keating MR; Anhalt JP; Steckelberg JM Mayo Clin Proc; 1989 Sep; 64(9):1097-104. PubMed ID: 2682049 [TBL] [Abstract][Full Text] [Related]
31. The antibiotic susceptibilities of Xanthomonas maltophilia and their relation to clinical management. Smit WJ; Boquest AL; Geddes JE; Tosolini FA Pathology; 1994 Jul; 26(3):321-4. PubMed ID: 7991292 [TBL] [Abstract][Full Text] [Related]
32. The role of lipopolysaccharide anionic binding sites in aminoglycoside uptake in Stenotrophomonas (Xanthomonas) maltophilia. Vanhoof R; Sonck P; Hannecart-Pokorni E J Antimicrob Chemother; 1995 Jan; 35(1):167-71. PubMed ID: 7768765 [TBL] [Abstract][Full Text] [Related]
33. Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gram-negative bacilli: occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes. Jones RN; Pfaller MA; Marshall SA; Hollis RJ; Wilke WW Diagn Microbiol Infect Dis; 1997 Nov; 29(3):187-92. PubMed ID: 9401811 [TBL] [Abstract][Full Text] [Related]
34. Effect of divalent cations in bacteriological media on the susceptibility of Xanthomonas maltophilia to imipenem, with special reference to zinc ions. Hawkey PM; Birkenhead D; Kerr KG; Newton KE; Hyde WA J Antimicrob Chemother; 1993 Jan; 31(1):47-55. PubMed ID: 8444674 [TBL] [Abstract][Full Text] [Related]
35. Antibiotic susceptibility and outer membrane proteins of clinical Xanthomonas maltophilia isolates. Cullmann W Chemotherapy; 1991; 37(4):246-50. PubMed ID: 1790722 [TBL] [Abstract][Full Text] [Related]
36. Synergistic interactions of ciprofloxacin and extended-spectrum beta-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophilia. Chow AW; Wong J; Bartlett KH Antimicrob Agents Chemother; 1988 May; 32(5):782-4. PubMed ID: 3395107 [TBL] [Abstract][Full Text] [Related]
37. In vitro susceptibility of 33 clinical case isolates of Xanthomonas maltophilia. Inconsistent correlation of agar dilution and of disk diffusion test results. Hohl P; Frei R; Aubry P Diagn Microbiol Infect Dis; 1991; 14(5):447-50. PubMed ID: 1797460 [TBL] [Abstract][Full Text] [Related]
38. Enzymatic resistance to beta-lactams and aminoglycosides in Acinetobacter calcoaceticus. Joly-Guillou ML; Bergogne-Bérézin E; Moreau N J Antimicrob Chemother; 1987 Dec; 20(6):773-6. PubMed ID: 3440769 [No Abstract] [Full Text] [Related]
39. In vitro antibacterial activity and beta-lactamase stability of CP-70,429 a new penem antibiotic. Minamimura M; Taniyama Y; Inoue E; Mitsuhashi S Antimicrob Agents Chemother; 1993 Jul; 37(7):1547-51. PubMed ID: 8363389 [TBL] [Abstract][Full Text] [Related]
40. Kinetics of antimicrobial activity of aztreonam/clavulanic acid (2:1) against Xanthomonas maltophilia. García-Rodríguez JA; García Sánchez JE; Muñoz Bellido JL; García García MI; García Sánchez E J Antimicrob Chemother; 1991 Apr; 27(4):552-4. PubMed ID: 1856134 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]